VEGFD and lymphedema: Our finding that the D103A mutant of mature VEGF-D exhibits enhanced potency for VEGFR-3 could be of clinical significance because this protein, or derivatives thereof, could potentially be used therapeutically to drive lymphangiogenesis and lymphatic remodeling in lymphedema and inflammatory conditions.